Methanesulfonic acid (S)-3-hydroxy-4-methanesulfonyloxy-2,2-dimethyl-butyl ester | 511268-36-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: Methanesulfonic acid (S)-3-hydroxy-4-methanesulfonyloxy-2,2-dimethyl-butyl ester
• 英文别名: (2S)-2-hydroxy-3,3-dimethyl-4-[(methylsulfonyl)oxy]butyl methanesulfonate；[(2S)-2-hydroxy-3,3-dimethyl-4-methylsulfonyloxybutyl] methanesulfonate
• CAS: 511268-36-3
• 化学式: C₈H₁₈O₇S₂
• 分子量: 290.359
• InChiKey: YPKWEVDJNIRMMT-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  124
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Methanesulfonic acid (S)-3-hydroxy-4-methanesulfonyloxy-2,2-dimethyl-butyl ester 在 palladium on activated charcoal 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 吡啶 、 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 生成 {(S)-1-[(R)-Hydroxy-((R)-1-phenyl-ethylcarbamoyl)-methyl]-pentyl}-carbamic acid (S)-4,4-dimethyl-pyrrolidin-3-yl ester
  参考文献：
  名称：

  Novel, potent P2–P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors

  摘要：

  Starting from a potent pantolactone ketoamide cathepsin K inhibitor discovered from structural screening, conversion of the lactone scaffold to a pyrrolidine scaffold allowed exploration of the S(3) subsite of cathepsin K. Manipulation of P3 and P1' groups afforded potent inhibitors with drug-like properties.

  DOI：

  10.1016/j.bmcl.2005.11.101
• 作为产物：
  描述：

  (S)-(+)-泛解酸内酯 在 sodium tetrahydroborate 作用下， 以 吡啶 、 甲醇 为溶剂， 生成 Methanesulfonic acid (S)-3-hydroxy-4-methanesulfonyloxy-2,2-dimethyl-butyl ester
  参考文献：
  名称：

  Novel, potent P2–P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors

  摘要：

  Starting from a potent pantolactone ketoamide cathepsin K inhibitor discovered from structural screening, conversion of the lactone scaffold to a pyrrolidine scaffold allowed exploration of the S(3) subsite of cathepsin K. Manipulation of P3 and P1' groups afforded potent inhibitors with drug-like properties.

  DOI：

  10.1016/j.bmcl.2005.11.101

文献信息

• Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss
  申请人：Barrett Gene David

  公开号：US20050245596A1

  公开（公告）日：2005-11-03

  Heterocycle substituted ketoamide derivatives of Formula (I), wherein the substitutes A, D, A and R are defined as in claim in, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such heterocycle substituted ketoamide derivatives as well as method of using the same in the manufacture of medicaments for the treatment of disorders, including osteoporosis, associated with an imbalance between bone resorption and formation which can ultimately lead to fracture.

  本文描述了公式(I)的杂环取代酮酰胺衍生物，其中替代基A、D、A和R如权利要求中所定义，这些衍生物可用作卡特普西林K抑制剂。所述发明还包括制备这种杂环取代酮酰胺衍生物的方法，以及使用它们制造治疗与骨吸收和形成失衡有关的疾病（例如骨质疏松症），最终可能导致骨折的药物的方法。
• Propylcarbamate derivatives as inhibitors of serine and cysteine proteases
  申请人：Deaton Norman David

  公开号：US20050043368A1

  公开（公告）日：2005-02-24

  The present invention includes ketone derivatives (I) and (II), which are useful as cathepsin K inhibitors. The described invention also includes methods of making such ketone derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis.

  本发明涉及酮衍生物（I）和（II），其作为猫hepsin K抑制剂具有用途。所述发明还包括制备此类酮衍生物的方法，以及使用它们治疗疾病的方法，包括骨质疏松症。
• Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss
  申请人：SmithKline Beecham Corporation

  公开号：US07402606B2

  公开（公告）日：2008-07-22

  Heterocycle substituted ketoamide derivatives of Formula (I), wherein the substitutes A, D, A and R are defined as in claim in, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such heterocycle substituted ketoamide derivatives as well as method of using the same in the manufacture of medicaments for the treatment of disorders, including osteoporosis, associated with an imbalance between bone resorption and formation which can ultimately lead to fracture.

  本文描述了公式（I）的杂环取代酮酰胺衍生物，其中替代物A、D、A和R如权利要求中所定义，这些衍生物对于作为卡他普星K抑制剂是有用的。所述发明还包括制备这种杂环取代酮酰胺衍生物的方法，以及使用它们制造治疗与骨吸收和形成不平衡相关的疾病，包括骨质疏松症，最终可能导致骨折的药物的方法。
• PROPYLCARBAMATE DERIVATIVES AS INHIBITORS OF SERINE AND CYSTEINE PROTEASES
  申请人：SmithKline Beecham Corporation

  公开号：EP1448554A1

  公开（公告）日：2004-08-25
• DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS
  申请人：SmithKline Beecham Corporation

  公开号：EP1494663A1

  公开（公告）日：2005-01-12